From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

Project Facilitate: Enhancing the Single Patient IND Process for Oncology
May 16, 2019   |   1:00 PM to 3:30 PM FDA White Oak Campus Building 31, Room 1503 - Great Room
2019 Annual Public Meeting
Annual Public Meeting Set for May 2, 2019
Collecting Data from EA Treatment for Regulatory Submissions Presentation
Executive Director June Wasser will present Collecting Data from EA Treatment for Regulatory Submissions at the Life Science Compassionate Access Summit at 4:00 pm, Monday, March 18th in Philadelphia.
2018 Innovations in Regulatory Science Awards Dinner
The Reagan-Udall Foundation for the FDA honored two longtime U.S.
Leveraging Real-World Treatment Experience from EA Protocols
See Event Highlights and Download the Meeting Report 
Expanded Access Programs and Real-World Evidence: Public Meeting
Expanded access programs, sometimes also called “compassionate use” programs, provide patients with serious or immediately life-threatening diseases or conditions access to investigational products outside of clinical tria
2024 Innovations in Regulatory Science Awards
2023 Innovations in Regulatory Science Awards
RDBA and FDA Foundation Partner to Provide Turnkey Resources to Retail Dietitians - The Associated Press
Today, the Reagan-Udall Foundation for the FDA (FDA Foundation) and the Retail Dietitians Business Alliance (RDBA) jointly launched Supporting Healthier Eating in the New Normal: The Ultimate Retail Dietitians Toolkit.
Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments - The Journal Drugs
More than 32 million individuals have survived a confirmed COVID-19 viral infection in the USA [1, 2], and a substantial proportion of post-COVID survivors are suffering from prolonged, recurrent, and/or newly emerging symptoms that span across bodily systems and organs [3]. The spectrum of symptoms and disabilities observed in this setting has been alarming and suggests that the “post-COVID syndrome” is a pan-inflammatory disease with highly variable disease expression and consequences [4]. However, accurately and completely characterizing post-COVID syndrome is difficult because many individuals with acute COVID-19 infection were not hospitalized, and therefore were not tracked through standard, in-patient-based data reporting mechanisms to public health authorities [5].